Lachman Consultants is attending the TIDES USA 2026 conference this week in Boston, one of the premier events focused on oligonucleotide and peptide therapeutics, CMC, manufacturing, quality, and regulatory strategy.
As the biopharmaceutical industry continues to advance innovative modalities and complex therapies, TIDES provides an important forum for collaboration, technical insight, and regulatory discussion across the product lifecycle.
Representing the Lachman team at this year’s conference will be Mrinmoy Nag, Senior Director in the Biologics and Compliance practice areas, who will be connecting with industry leaders and discussing the evolving regulatory and quality considerations impacting the development and commercialization of advanced therapeutics.
If you are attending TIDES this week, we welcome the opportunity to connect and discuss how Lachman Consultants supports organizations with strategic regulatory guidance, quality systems, compliance, and CMC expertise across the pharmaceutical and biotechnology sectors. Contact Lachman Consultants here.
We look forward to seeing everyone in Boston.
About Mrinmoy Nag
Mrinmoy Nag brings more than 25 years of biopharmaceutical industry experience spanning quality, compliance, and CMC leadership across clinical development through commercial cGMP manufacturing. His expertise includes method development and validation for biologics, peptides, and cell and gene therapies, as well as the implementation and management of global GMP quality systems.
